Fig. 2: Tumor subtyping and CCCA in patients from PALLET.

a Pie chart of subtype distributions by the RNAseq-AIMS and RNAseq-PAM50.sgMd.TC subtyping methods for PALLET samples. b Odds ratios and 95% CIs for non-CCCA by breast cancer RNAseq-AIMS and RNAseq-PAM50.sgMd.TC subtype in PALLET. LET letrozole, n number of patients in the subtype treatment group, PAL palbociclib.